Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective of Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

NCT04137588 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT04137588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective of Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Unknown status
Start date
March 3, 2021
Completion date
June 1, 2022
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-squamous non-small cell lung cancer